MPM BioImpact is a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in companies that seek to translate scientific innovations into cures for major diseases. With its world-class team and deep experience in scientific research, clinical development, and company-building, MPM BioImpact strives to power novel medical breakthroughs that transform patients’ lives. MPM BioImpact invests across the biotech landscape from early stage start-ups to public companies.
Location: United States, California, San Francisco
Portfolio 28
| Date | Name | Website | Total Raised | Location |
| - | Crossbow T... | crossbowtx.com | $80M | United Sta... |
| - | Firefly Bi... | fireflybiologics.com | - | - |
| - | Cullinan O... | cullinanoncology.com | $379.7M | United Sta... |
| - | Antiva Bio... | antivabio.com | $137M | United Sta... |
| - | Tizona The... | tizonatx.com | $343M | United Sta... |
| - | Frontier M... | frontiermeds.com | $235.5M | United Sta... |
| - | AstronauTx | astronautx.bio | $61M | - |
| - | Werewolf T... | werewolftx.com | $128M | United Sta... |
| - | Twentyeigh... | twentyeight-seven.com | $80M | - |
| - | Adaptimmun... | adaptimmune.com | $104M | United Kin... |
Show more
Mentions in press and media 12
| Date | Title | Description |
| 31.08.2026 | Singapore’s biotechnology firm K2 Therapeutics raises $50 M Seed funding from MPM BioImpact | The U.S. investment firm MPM BioImpact, which formed Singapore-based biotechnology business K2 Therapeutics in 2024, has provided $50 million in seed funding. K2 Therapeutics said in a statement on Tuesday that the funding has enabled the c... |
| 25.08.2026 | Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases | SHANGHAI and HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializi... |
| 24.08.2026 | Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D | SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializi... |
| 20.07.2026 | Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026 | SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializi... |
| 22.06.2026 | Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE | ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ... |
| 12.05.2026 | AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer | London, UK, 12 May 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological disorders by improving sleep architecture, announces the appointments of Dr. Michel... |
| 22.03.2026 | Crossbow Therapeutics Fuels T-Cell Engager Pipeline with $77 Million Series B | Crossbow Therapeutics secured $77 million in Series B funding to propel its innovative TCR-mimetic antibody cancer therapies. This substantial capital injection will accelerate the development of critical T-cell engager programs. Funds will... |
| 19.03.2026 | Crossbow Therapeutics Raises $77M in Series B Funding | Crossbow Therapeutics, a Cambridge, MA-based biotechnology company developing antibody therapies to treat a broad range of cancers, raised $77M in Series B funding. The round was led by Taiho Ventures and Arkin Bio Capital, with participati... |
| 18.03.2026 | Crossbow Therapeutics: $77 Million Raised To Advance TCR-Mimetic Antibody Cancer Therapies | Crossbow Therapeutics announced it has raised $77 million in a Series B financing to advance the development of its TCR-mimetic antibody therapies designed to treat a broad range of cancers. The funding round was co-led by Taiho Ventures an... |
| 06.03.2026 | FDA reversals leave investors worrying about the fates of other experimental drugs | The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna’s flu shot before reversing course. Companies have accused the FDA of ... |
Show more